Runze You

P1.074. SNORD33-Driven 18S rRNA 2′-O-Methylation Licenses TNFSF9–4-1BB Signaling and Sensitizes ESCC to PD-1 Blockade

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Neoadjuvant PD-1/PD-L1 based immunotherapy improve outcomes for resectable esophageal squamous cell carcinoma (ESCC), but patient outcome are heterogeneous and robust pretreatment blood biomarkers ar...

OA03-RF01.07. Neoadjuvant Chemoimmunotherapy Versus Upfront Surgery for Clinical T2N0 Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background The role of neoadjuvant chemoimmunotherapy (nICT) in clinical T2N0 (cT2N0) esophageal squamous cell carcinoma (ESCC) remains controversial. Current guidelines recommend upfront surgery for this popul...